SARS-CoV-2 pathogenesis in human and bat cells and development of in vitro and in vivo infection models
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:8 publications
Grant number: 170645
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$561,348.41Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Karen L MossmanResearch Location
CanadaLead Research Institution
McMaster UniversityResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Animal source and routes of transmission
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Severe acute respiratory syndrome coronavirus - 2 (SARS-CoV-2) emerged in December 2019 and has infected over 60,000 people, of which over 1800 have died. SARS-CoV-2 shares 96% similarity with a coronavirus found in bats. Bats have been shown to carry a diversity of viruses including coronaviruses globally, without showing signs of disease. Also, major circulating and endemic coronaviruses that are causing disease in humans are speculated to have evolved in bats. Our team's extensive experience in studying coronaviruses in bat and human systems, will allow us to understand interactions of SARS-CoV-2 in bats and humans using a holistic 'One Health' approach. The main objectives of our proposal are to investigate how cell anti-viral responses are induced in human (spillover host) and bat (reservoir host) cells, and to develop animal models to facilitate rapid testing of vaccine candidates and therapeutics.
Publicationslinked via Europe PMC
Last Updated:14 hours ago
View all publications at Europe PMC